1. Home
  2. HSDT vs ATXG Comparison

HSDT vs ATXG Comparison

Compare HSDT & ATXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSDT
  • ATXG
  • Stock Information
  • Founded
  • HSDT N/A
  • ATXG 2014
  • Country
  • HSDT United States
  • ATXG China
  • Employees
  • HSDT 21
  • ATXG N/A
  • Industry
  • HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ATXG Professional Services
  • Sector
  • HSDT Health Care
  • ATXG Consumer Discretionary
  • Exchange
  • HSDT Nasdaq
  • ATXG Nasdaq
  • Market Cap
  • HSDT 4.2M
  • ATXG 3.8M
  • IPO Year
  • HSDT N/A
  • ATXG N/A
  • Fundamental
  • Price
  • HSDT $5.94
  • ATXG $0.45
  • Analyst Decision
  • HSDT Hold
  • ATXG
  • Analyst Count
  • HSDT 1
  • ATXG 0
  • Target Price
  • HSDT N/A
  • ATXG N/A
  • AVG Volume (30 Days)
  • HSDT 993.8K
  • ATXG 243.5K
  • Earning Date
  • HSDT 08-14-2025
  • ATXG 08-14-2025
  • Dividend Yield
  • HSDT N/A
  • ATXG N/A
  • EPS Growth
  • HSDT N/A
  • ATXG N/A
  • EPS
  • HSDT N/A
  • ATXG N/A
  • Revenue
  • HSDT $295,000.00
  • ATXG $4,310,835.00
  • Revenue This Year
  • HSDT N/A
  • ATXG N/A
  • Revenue Next Year
  • HSDT $75.13
  • ATXG N/A
  • P/E Ratio
  • HSDT N/A
  • ATXG N/A
  • Revenue Growth
  • HSDT N/A
  • ATXG N/A
  • 52 Week Low
  • HSDT $5.37
  • ATXG $0.36
  • 52 Week High
  • HSDT $1,200.00
  • ATXG $1.86
  • Technical
  • Relative Strength Index (RSI)
  • HSDT 24.77
  • ATXG 42.00
  • Support Level
  • HSDT $5.75
  • ATXG $0.43
  • Resistance Level
  • HSDT $6.04
  • ATXG $0.48
  • Average True Range (ATR)
  • HSDT 0.43
  • ATXG 0.05
  • MACD
  • HSDT 2.01
  • ATXG 0.00
  • Stochastic Oscillator
  • HSDT 22.88
  • ATXG 55.34

About HSDT Helius Medical Technologies Inc. (DE)

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

About ATXG Addentax Group Corp.

Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.

Share on Social Networks: